PATIENT ENGAGEMENT IS THE MOST IMPORTANT FACTOR IN DEVELOPING THE MEDTECH SECTOR
New survey of science industry specialists revealed:
- Overall, 96% of respondents felt patient engagement was important in developing new medical technologies; with 66% revealing it was very important, while 30% felt it was slightly important
- 36% of respondents highlighted a focus on developing digitally enabled products and services as key to driving medical technology, above data mining (32%) and the use of social media (18%)
- 35% of respondents revealed a higher level of government support in Dubai will drive growth in the medtech sector, whilst 29% believed attracting more international companies
Dubai, UAE: Patient engagement is crucial in developing new medical technologies, according to a new survey by Dubai Science Park (DSP), the free zone community dedicated to facilitating and fostering the growth of the UAE’s science sector.
The survey of around 100 science sector executives revealed that 96% of respondents found patient engagement was important in developing new medical technologies, with 66% revealing it was very important, while 30% felt it was slightly important.
36% of respondents also believed a focus on developing digitally enabled products and services as a key driver of medical technology, above data mining (32%) and the use of social media (18%).
The results reveal the importance of companies in the science industry to truly understand their customers, and how they interact with medical services in the region in order to rerate the most relevant and effective tools. Whilst also highlighting the importance of customer engagement, placing end user experience is vital for the medical sector to progress.
Speaking at the DSP’s Arab Health Gala Dinner, Marwan Abdulaziz, Executive Director, DSP commented: “The perspective of the end user affected by medtech products matters the most – as these patients are the ones that have to use and handle these devices in everyday life. Customer engagement is essential, and must take a leading role when considering a new product to ensure medtech companies deliver solutions for patient’s needs.
“At DSP we aim to facilities innovative growth and progression within the science sector, and the results of this survey show the need for better communication with patients to ensure they are receiving the best possible solutions, advancing the healthcare and quality of care.
The survey also found that 35% of respondents believed a higher level of government support would drive Dubai’s growth in the medtech sector. Whilst 29% believed attracting further international companies, and 23% thought a higher skill set from local talent would be the driving force behind development in the sector.
Dubai Science Park (DSP) is the region’s first free zone community that serves the value chain of the science sector, including science entrepreneurs, SMEs and multinational enterprises. Formerly known as DuBiotech and EnPark, it is home almost 300 science companies from across the value chain.